Azitra, Inc. (NYSEAMERICAN:AZTR) Short Interest Down 68.2% in May

Azitra, Inc. (NYSEAMERICAN:AZTR) saw a significant decline in short interest during the month of May. As of May 15th, there was short interest totaling 126,538 shares, a decline of 68.2% from the April 30th total of 397,818 shares. Based on an average daily trading volume, of 471,811 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.8% of the shares of the company are short sold.

Azitra Trading Up 12.0%

Shares of NYSEAMERICAN:AZTR traded up $0.02 during trading on Friday, reaching $0.23. The company had a trading volume of 1,357,101 shares, compared to its average volume of 523,294. The stock’s fifty day moving average price is $0.23 and its 200 day moving average price is $0.25. Azitra has a fifty-two week low of $0.10 and a fifty-two week high of $2.40.

Azitra (NYSEAMERICAN:AZTR) last released its earnings results on Wednesday, May 13th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.24). Equities analysts anticipate that Azitra will post -0.25 EPS for the current year.

Azitra Company Profile

Azitra Inc is a clinical-stage biopharmaceutical company focused on developing live bacterial therapies for dermatological conditions. Headquartered in Cambridge, Massachusetts, the company leverages its proprietary ActoBiotic platform to formulate topical treatments that aim to modulate the skin’s native microbial ecosystem.

The company’s lead investigational therapies are being evaluated in early-phase clinical studies for inflammatory skin disorders, including atopic dermatitis and other conditions characterized by microbial imbalance.